Research programme: allergy vaccines - Acambis/GlaxoSmithKline

Drug Profile

Research programme: allergy vaccines - Acambis/GlaxoSmithKline

Alternative Names: Allergy vaccines research programme - Acambis/GlaxoSmithKline

Latest Information Update: 21 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis; GlaxoSmithKline
  • Class Vaccines
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 12 May 2004 Suspended - Preclinical for Allergy in United Kingdom (unspecified route)
  • 20 Mar 2001 New profile
  • 20 Mar 2001 Preclinical development for Allergy in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top